Expected Increase of Profit for Intrexon Corp (XON)
Analysts await Intrexon Corp (NYSE:XON) to reports earnings on February, 29 after the close. They expect $-0.18 earnings per share, down 200.00 % or $0.36 from last year’s $0.18 per share. After $-0.34 actual earnings per share reported by Intrexon Corp for the previous quarter, Wall Street now forecasts -47.06 % EPS growth. The stock increased 7.00% or $2.21 on February 26, hitting $33.76. About 1.58M shares traded hands. Intrexon Corp (NYSE:XON) has declined 42.04% since July 23, 2015 and is downtrending. It has underperformed by 34.71% the S&P500.
Out of 4 analysts covering Intrexon Corp (NYSE:XON), 2 rate it “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Intrexon Corp was the topic in 16 analyst reports since March 3, 2015 according to StockzIntelligence Inc. Mizuho upgraded the stock on November 11 to “Neutral” rating.
The institutional sentiment decreased to 1.41 in Q2 2015. Its down 0.65, from 2.06 in 2015Q1. The ratio fall, as 24 funds sold all Intrexon Corp shares owned while 45 reduced positions. 37 funds bought stakes while 60 increased positions. They now own 94.52 million shares or 2.42% more from 92.28 million shares in 2015Q1.
Third Security Llc holds 78.75% of its portfolio in Intrexon Corp for 61.72 million shares. University Of Texas Investment Managment Co owns 2.10 million shares or 36.62% of their US portfolio. Moreover, Michael & Susan Dell Foundation has 14.64% invested in the company for 521,878 shares. The Texas-based Belmont Global Advisors Inc. has invested 9.25% in the stock. Oracle Investment Management Inc, a Connecticut-based fund reported 876,502 shares.
Intrexon Corporation is engaged in the field of synthetic biology. The company has a market cap of $3.84 billion. The Firm designs, manufactures and regulates gene programs, which are Deoxyribonucleic Acid sequences that consist of genetic components. It currently has negative earnings. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells.
Intrexon Corp – Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
Tagged: Intrexon Corp – (NYSE:XON)